Christopher V. Almario
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher V. Almario has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Brennan Mason Ross Spiegel
Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
19 shared publications - Carine Khalil
Paris Descartes University
11 shared publications Brennan M.R. Spiegel
7 shared publicationsSo Yung Choi
Biostatistics Shared Resource Cedars‐Sinai Cancer Los Angeles California USA
6 shared publicationsBrennan M. R. Spiegel
Cedars‐Sinai Center for Virtual Medicine and Health System Transformation Los Angeles California USA
5 shared publicationsCarine Khalil
Division of Health Services Research Cedars‐Sinai Medical Center, Center for Outcomes Research and Education (CS‐CORE) Los Angeles California USA
5 shared publications
Latest Publications
- 4 September 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (9)
Patients' Real‐World Experiences With Pharmacologic Therapies for Irritable Bowel Syndrome With Constipation: A Mixed‐Methods Analysis and Classification of Social Media and E‐Forum Posts
Background: Irritable bowel syndrome with constipation (IBS‐C) is a common disorder of gut–brain interaction that significantly impairs quality of life. Although multiple US Food and Drug Administration (FDA)‐approved medications have demonstrated efficacy in randomized controlled trials, less is known about patients' real‐world experiences and factors influencing treatment decisions. Here, we conducted social media netnography—a qualitative approach for examining patient perspectives posted online on social media platforms and e‐health forums, exploring the perspectives and experiences of IBS‐C patients who report using FDA‐approved therapies. Methods: We examined publicly available posts from X and online health e‐forums (Reddit, WebMD, ibspatient.org ) made between 9/19/2007 and 9/12/2024. Overall, 7328 relevant posts referencing FDA‐approved IBS‐C medications (linaclotide, lubiprostone, plecanatide, tegaserod, tenapanor) were included. We employed qualitative (open coding) and quantitative approaches (natural language processing and artificial intelligence) to analyze the posts. Results: Four major themes emerged: (i) perceived medication efficacy; (ii) treatment‐related burden; (iii) intentional non‐adherence; and (iv) barriers to adherence. Patients described heterogeneous efficacy, ranging from meaningful symptom relief to limited or no benefit. Patients discussed the biopsychosocial burden of IBS‐C medications (e.g., nausea, frustration, social anxiety from potential diarrheal side effects), highlighting various barriers to adherence. Barriers such as cost, insurance coverage, and personal beliefs also influenced decisions, often prompting discontinuation, dose adjustments, or pursuit of alternative therapies. Conclusions: Social media provides unique insights into IBS‐C patients' real‐world experiences with FDA‐approved therapies. Findings highlight variability in efficacy, biopsychosocial impacts, and adherence challenges, underscoring the need for shared decision making and proactive management of barriers to optimize outcomes.
- 4 September 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (9)
Patients' Real‐World Experiences With Pharmacologic Therapies for Irritable Bowel Syndrome With Constipation: A Mixed‐Methods Analysis and Classification of Social Media and E‐Forum Posts
Background: Irritable bowel syndrome with constipation (IBS‐C) is a common disorder of gut–brain interaction that significantly impairs quality of life. Although multiple US Food and Drug Administration (FDA)‐approved medications have demonstrated efficacy in randomized controlled trials, less is known about patients' real‐world experiences and factors influencing treatment decisions. Here, we conducted social media netnography—a qualitative approach for examining patient perspectives posted online on social media platforms and e‐health forums, exploring the perspectives and experiences of IBS‐C patients who report using FDA‐approved therapies. Methods: We examined publicly available posts from X and online health e‐forums (Reddit, WebMD, ibspatient.org ) made between 9/19/2007 and 9/12/2024. Overall, 7328 relevant posts referencing FDA‐approved IBS‐C medications (linaclotide, lubiprostone, plecanatide, tegaserod, tenapanor) were included. We employed qualitative (open coding) and quantitative approaches (natural language processing and artificial intelligence) to analyze the posts. Results: Four major themes emerged: (i) perceived medication efficacy; (ii) treatment‐related burden; (iii) intentional non‐adherence; and (iv) barriers to adherence. Patients described heterogeneous efficacy, ranging from meaningful symptom relief to limited or no benefit. Patients discussed the biopsychosocial burden of IBS‐C medications (e.g., nausea, frustration, social anxiety from potential diarrheal side effects), highlighting various barriers to adherence. Barriers such as cost, insurance coverage, and personal beliefs also influenced decisions, often prompting discontinuation, dose adjustments, or pursuit of alternative therapies. Conclusions: Social media provides unique insights into IBS‐C patients' real‐world experiences with FDA‐approved therapies. Findings highlight variability in efficacy, biopsychosocial impacts, and adherence challenges, underscoring the need for shared decision making and proactive management of barriers to optimize outcomes.
- Open Access
- 20 August 2026
- Published by Elsevier in Clinical Gastroenterology and Hepatology
A Single Question on Quality-of-Life Improvement Identifies Treatment Satisfaction in Irritable Bowel Syndrome
- 20 August 2026
- Published by Elsevier in Clinical Gastroenterology and Hepatology
Open AccessA Single Question on Quality-of-Life Improvement Identifies Treatment Satisfaction in Irritable Bowel Syndrome
- 2 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF11
Preferences for Blood-Based Versus Traditional Screening Modalities for Lung and Colorectal Cancers: Insights from a Conjoint Analysis Among US Adults
Background: More than 80% of eligible adults who smoke are not up to date with lung cancer screening, and >40% are overdue for colorectal cancer screening. Blood-based screening tests may offer a less burdensome alternative to existing modalities. We used conjoint analysis to assess preferences for blood-based lung cancer and colorectal cancer screening compared with traditional methods [low-dose computed tomography (LDCT) for lung cancer; stool tests or colonoscopy for colorectal cancer]. Methods: An online choice-based conjoint survey was administered to US adults aged 50 to 75 years who were not up to date with lung cancer and colorectal cancer screening. To recruit respondents, we collaborated with a survey research firm (Cint) that partners with multiple survey panels across the United States. Participants compared hypothetical screening test combinations varying in modality, frequency, and accuracy. Simulations identified preferred screening strategies, and logistic regression examined factors associated with preferring blood-based screening. Results: Among 1,741 participants, 43.9% preferred blood tests every 3 years for both cancers, whereas 28.6% favored traditional screening for both. Another 21.9% preferred a blood test for lung cancer and a traditional colorectal cancer test, and 5.6% chose LDCT with a colorectal cancer blood test. Nonmarried individuals, those with comorbidities, and those who exercised infrequently were more likely to prefer blood-based screening (P < 0.05). Conversely, non-Hispanic Black participants and higher-income individuals were less likely to choose blood tests (P < 0.05). Conclusions: Nearly half of adults not up to date with lung cancer and colorectal cancer screening preferred blood-based testing for both cancers. Impact: Blood-based tests may help reduce barriers and improve lung cancer and colorectal cancer screening uptake.
- 2 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF11
Preferences for Blood-Based Versus Traditional Screening Modalities for Lung and Colorectal Cancers: Insights from a Conjoint Analysis Among US Adults
Background: More than 80% of eligible adults who smoke are not up to date with lung cancer screening, and >40% are overdue for colorectal cancer screening. Blood-based screening tests may offer a less burdensome alternative to existing modalities. We used conjoint analysis to assess preferences for blood-based lung cancer and colorectal cancer screening compared with traditional methods [low-dose computed tomography (LDCT) for lung cancer; stool tests or colonoscopy for colorectal cancer]. Methods: An online choice-based conjoint survey was administered to US adults aged 50 to 75 years who were not up to date with lung cancer and colorectal cancer screening. To recruit respondents, we collaborated with a survey research firm (Cint) that partners with multiple survey panels across the United States. Participants compared hypothetical screening test combinations varying in modality, frequency, and accuracy. Simulations identified preferred screening strategies, and logistic regression examined factors associated with preferring blood-based screening. Results: Among 1,741 participants, 43.9% preferred blood tests every 3 years for both cancers, whereas 28.6% favored traditional screening for both. Another 21.9% preferred a blood test for lung cancer and a traditional colorectal cancer test, and 5.6% chose LDCT with a colorectal cancer blood test. Nonmarried individuals, those with comorbidities, and those who exercised infrequently were more likely to prefer blood-based screening (P < 0.05). Conversely, non-Hispanic Black participants and higher-income individuals were less likely to choose blood tests (P < 0.05). Conclusions: Nearly half of adults not up to date with lung cancer and colorectal cancer screening preferred blood-based testing for both cancers. Impact: Blood-based tests may help reduce barriers and improve lung cancer and colorectal cancer screening uptake.
- 7 November 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (12) , e70200
Racial and Ethnic Disparities in Pandemic‐Onset Disorders of Gut–Brain Interaction: Results From a Nationwide Survey
Background: During the COVID‐19 pandemic, the prevalence of disorders of gut–brain interaction (DGBI) in the US increased. The pandemic also led to health inequities among racial and ethnic minorities. Here, we conducted monthly national surveys during the pandemic to examine the association between race/ethnicity and pandemic‐onset DGBI. Methods: From March 2021 to May 2022, we recruited a nationally representative sample of adults in the US to complete an online survey with Rome IV questionnaires (9 gastroduodenal and bowel DGBI) along with demographic and comorbidity questions. Participants with a DGBI were asked whether their cardinal symptoms started before or after the COVID‐19 pandemic began in the US (March 2020). Our primary outcome was the prevalence of pandemic‐onset DGBI. Multivariable logistic regression models identified factors associated with pandemic‐onset DGBI. We also tested for an interaction between race/ethnicity and COVID‐19 positivity to assess whether the relationship between pandemic‐onset DGBI and race/ethnicity varied by COVID‐19 status. Results: Among 71,547 respondents, 26,103 (36.5%) had ≥ 1 DGBI. Across most DGBI, non‐Hispanic Blacks and Hispanics had higher odds for pandemic‐onset DGBI (e.g., irritable bowel syndrome, functional dyspepsia, functional bloating) versus non‐Hispanic Whites. When including interaction terms between race/ethnicity and COVID‐19 positivity, most were not significant ( p > 0.05), showing that the relationship between pandemic‐onset DGBIs and race/ethnicity did not vary by COVID‐19 status. Conclusions: In this US survey, racial/ethnic minorities had higher odds of reporting pandemic‐onset DGBI. This association was independent of COVID‐19 positivity, suggesting that differences in pandemic‐onset DGBI among groups may be related to psychosocial challenges faced by racial/ethnic minorities rather than direct effects of SARS‐CoV‐2.
- 7 November 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (12) , e70200
Racial and Ethnic Disparities in Pandemic‐Onset Disorders of Gut–Brain Interaction: Results From a Nationwide Survey
Background: During the COVID‐19 pandemic, the prevalence of disorders of gut–brain interaction (DGBI) in the US increased. The pandemic also led to health inequities among racial and ethnic minorities. Here, we conducted monthly national surveys during the pandemic to examine the association between race/ethnicity and pandemic‐onset DGBI. Methods: From March 2021 to May 2022, we recruited a nationally representative sample of adults in the US to complete an online survey with Rome IV questionnaires (9 gastroduodenal and bowel DGBI) along with demographic and comorbidity questions. Participants with a DGBI were asked whether their cardinal symptoms started before or after the COVID‐19 pandemic began in the US (March 2020). Our primary outcome was the prevalence of pandemic‐onset DGBI. Multivariable logistic regression models identified factors associated with pandemic‐onset DGBI. We also tested for an interaction between race/ethnicity and COVID‐19 positivity to assess whether the relationship between pandemic‐onset DGBI and race/ethnicity varied by COVID‐19 status. Results: Among 71,547 respondents, 26,103 (36.5%) had ≥ 1 DGBI. Across most DGBI, non‐Hispanic Blacks and Hispanics had higher odds for pandemic‐onset DGBI (e.g., irritable bowel syndrome, functional dyspepsia, functional bloating) versus non‐Hispanic Whites. When including interaction terms between race/ethnicity and COVID‐19 positivity, most were not significant ( p > 0.05), showing that the relationship between pandemic‐onset DGBIs and race/ethnicity did not vary by COVID‐19 status. Conclusions: In this US survey, racial/ethnic minorities had higher odds of reporting pandemic‐onset DGBI. This association was independent of COVID‐19 positivity, suggesting that differences in pandemic‐onset DGBI among groups may be related to psychosocial challenges faced by racial/ethnic minorities rather than direct effects of SARS‐CoV‐2.
- Open Access
- 27 October 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (1) , e00945
Patient Preferences for a Blood-Based Colorectal Cancer Screening Test: Insights From a Conjoint Analysis Survey
INTRODUCTION: Over one-third of people are not up-to-date with colorectal cancer (CRC) screening, and blood-based tests offer a promising alternative to existing options. We used conjoint analysis to quantify the proportion of people who would prefer a hypothetical blood test over current methods (e.g., fecal immunochemical test, multitarget stool DNA test, colonoscopy). METHODS: We conducted a conjoint analysis survey in a US nationally representative sample of average risk individuals aged 40–75 years who were not up-to-date with CRC screening. We performed latent class analysis to identify groups with similar decision-making profiles and estimated the proportion who would prefer a blood test every 3 years over existing methods. RESULTS: Overall, 1,009 participants completed the survey. Using latent class analysis, we identified 2 distinct groups: (i) prioritized how the test is performed—39.4%, and (ii) prioritized the accuracy of detecting CRC and advanced adenomas—60.6%. Through simulations using the conjoint data, most individuals in the first group preferred a blood test every 3 years (65.1%), whereas 53.0% of the second group also favored the blood test. In additional simulations that incorporated test accuracy for CRC and advanced adenoma detection, these performance characteristics emerged as important drivers of screening preferences across the different testing options. DISCUSSION: Among individuals not up-to-date with CRC screening, our findings suggest that many would generally prefer a blood-based screening test over other options, but preference may depend on test accuracy. Offering a blood test option may improve CRC screening uptake, particularly among individuals who are unscreened or overdue for screening.
- 27 October 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (1) , e00945
Open AccessPatient Preferences for a Blood-Based Colorectal Cancer Screening Test: Insights From a Conjoint Analysis Survey
INTRODUCTION: Over one-third of people are not up-to-date with colorectal cancer (CRC) screening, and blood-based tests offer a promising alternative to existing options. We used conjoint analysis to quantify the proportion of people who would prefer a hypothetical blood test over current methods (e.g., fecal immunochemical test, multitarget stool DNA test, colonoscopy). METHODS: We conducted a conjoint analysis survey in a US nationally representative sample of average risk individuals aged 40–75 years who were not up-to-date with CRC screening. We performed latent class analysis to identify groups with similar decision-making profiles and estimated the proportion who would prefer a blood test every 3 years over existing methods. RESULTS: Overall, 1,009 participants completed the survey. Using latent class analysis, we identified 2 distinct groups: (i) prioritized how the test is performed—39.4%, and (ii) prioritized the accuracy of detecting CRC and advanced adenomas—60.6%. Through simulations using the conjoint data, most individuals in the first group preferred a blood test every 3 years (65.1%), whereas 53.0% of the second group also favored the blood test. In additional simulations that incorporated test accuracy for CRC and advanced adenoma detection, these performance characteristics emerged as important drivers of screening preferences across the different testing options. DISCUSSION: Among individuals not up-to-date with CRC screening, our findings suggest that many would generally prefer a blood-based screening test over other options, but preference may depend on test accuracy. Offering a blood test option may improve CRC screening uptake, particularly among individuals who are unscreened or overdue for screening.
- Open Access
- 21 October 2025
- Vol. 7 (4)
Leveraging Social Media for Health Education: Dissemination of Crohn’s Perianal Fistula Educational Videos via Facebook and Instagram
Crohn’s perianal fistula (CPF) is a debilitating disease that significantly affects patients’ quality of life. Prior research revealed substantial knowledge gaps among individuals with CPF in accessing evidence-based educational resources. We evaluated the reach and engagement of two validated CPF educational videos and a companion website (HealMyFistula.org) that was disseminated through Facebook and Instagram. A six-month social media campaign was conducted to promote the CPF educational videos and website using targeted advertising strategies to maximize reach. Primary outcomes were the proportion of users who viewed at least 50% of a video and the outbound click rate to the website. Results were stratified by age, sex, and social media platform. The CPF Overview video reached 3.1 million users and had a ≥ 50% view rate of 3.31% (n = 103 463), while the CPF Treatment video reached 1.8 million users with a 1.40% view rate (n = 25 606). Older age groups showed significantly higher engagement, while females demonstrated higher view and click rates to HealMyFistula.org than males (P < .05). Facebook outperformed Instagram for the CPF Overview video, while Instagram slightly outperformed Facebook for the CPF Treatment video. Targeted social media campaigns can be effective in disseminating educational content. Engagement varied by video type, age, sex, and platform, showing the importance of demographically informed dissemination strategies. These findings suggest that health educational campaigns may benefit from tailoring content and dissemination strategies based on demographic engagement patterns.
- 21 October 2025
- Vol. 7 (4)
Open AccessLeveraging Social Media for Health Education: Dissemination of Crohn’s Perianal Fistula Educational Videos via Facebook and Instagram
Crohn’s perianal fistula (CPF) is a debilitating disease that significantly affects patients’ quality of life. Prior research revealed substantial knowledge gaps among individuals with CPF in accessing evidence-based educational resources. We evaluated the reach and engagement of two validated CPF educational videos and a companion website (HealMyFistula.org) that was disseminated through Facebook and Instagram. A six-month social media campaign was conducted to promote the CPF educational videos and website using targeted advertising strategies to maximize reach. Primary outcomes were the proportion of users who viewed at least 50% of a video and the outbound click rate to the website. Results were stratified by age, sex, and social media platform. The CPF Overview video reached 3.1 million users and had a ≥ 50% view rate of 3.31% (n = 103 463), while the CPF Treatment video reached 1.8 million users with a 1.40% view rate (n = 25 606). Older age groups showed significantly higher engagement, while females demonstrated higher view and click rates to HealMyFistula.org than males (P < .05). Facebook outperformed Instagram for the CPF Overview video, while Instagram slightly outperformed Facebook for the CPF Treatment video. Targeted social media campaigns can be effective in disseminating educational content. Engagement varied by video type, age, sex, and platform, showing the importance of demographically informed dissemination strategies. These findings suggest that health educational campaigns may benefit from tailoring content and dissemination strategies based on demographic engagement patterns.
- 25 March 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (4) , 363-371
Development and Validation of Crohn’s Perianal Fistula Educational Videos and Website for Increasing Patient Knowledge and Engagement
Introduction: There are few online resources that provide authoritative and comprehensive information on Crohn’s perianal fistula (CPF). In this study, we aimed to use a human-centered design thinking approach to develop and validate 2 educational CPF videos and an accompanying website to support patients with CPF. Methods: We used a design thinking approach to understand the unmet educational needs of patients with CPF. We conducted 3 rounds of interviews with a diverse sample of patients with CPF and used the resulting insights to iteratively develop 2 unbranded educational videos optimized for social media and an accompanying website. To validate the 2 videos, we performed an online survey with CPF patients to assess the impact of the videos on patient activation as measured by the patient activation measure (PAM). Results: Our design thinking approach with 20 CPF patients allowed us to empathize with them, gain an in-depth understanding of their informational needs, and iteratively test and update the educational materials based on their input. Using their feedback, we created 2 videos (“What is a Crohn’s perianal fistula?” and “How to treat Crohn’s perianal fistula?”) and a corresponding website called “Heal My Fistula.” In qualitative testing, patients described both videos and the website as “accurate”, “informative”, “simple”, “easy to understand”, and in line with their expectations. In validation testing through a pre-post survey (N=357), both videos led to statistically significant improvements in PAM scores ( P <0.001). Conclusion: Through a human-centered design thinking approach, we developed and validated 2 informative videos and a website (healmyfistula.org) for addressing the educational needs of patients with CPF.
- 25 March 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (4) , 363-371
Development and Validation of Crohn’s Perianal Fistula Educational Videos and Website for Increasing Patient Knowledge and Engagement
Introduction: There are few online resources that provide authoritative and comprehensive information on Crohn’s perianal fistula (CPF). In this study, we aimed to use a human-centered design thinking approach to develop and validate 2 educational CPF videos and an accompanying website to support patients with CPF. Methods: We used a design thinking approach to understand the unmet educational needs of patients with CPF. We conducted 3 rounds of interviews with a diverse sample of patients with CPF and used the resulting insights to iteratively develop 2 unbranded educational videos optimized for social media and an accompanying website. To validate the 2 videos, we performed an online survey with CPF patients to assess the impact of the videos on patient activation as measured by the patient activation measure (PAM). Results: Our design thinking approach with 20 CPF patients allowed us to empathize with them, gain an in-depth understanding of their informational needs, and iteratively test and update the educational materials based on their input. Using their feedback, we created 2 videos (“What is a Crohn’s perianal fistula?” and “How to treat Crohn’s perianal fistula?”) and a corresponding website called “Heal My Fistula.” In qualitative testing, patients described both videos and the website as “accurate”, “informative”, “simple”, “easy to understand”, and in line with their expectations. In validation testing through a pre-post survey (N=357), both videos led to statistically significant improvements in PAM scores ( P <0.001). Conclusion: Through a human-centered design thinking approach, we developed and validated 2 informative videos and a website (healmyfistula.org) for addressing the educational needs of patients with CPF.
- 10 March 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (4) , e70020
Trends in Prevalence of Rome IV Disorders of Gut‐Brain Interaction During the COVID‐19 Pandemic: Results From a Nationally Representative Sample of Over 160,000 People in the US
Background: We hypothesized that disorders of gut‐brain interaction (DGBI) increased during the pandemic due to the enteropathic nature of SARS‐CoV‐2, together with the potential for COVID‐19 pandemic‐related stress to negatively impact the gut‐brain axis. To test our hypothesis, we conducted a series of pre‐specified cross‐sectional surveys initiated at the beginning of the pandemic to trend the prevalence of Rome IV DGBI over time among a nationally representative sample of more than 160,000 people in the US. Methods: From May 2020 to May 2022, we performed a series of cross‐sectional online surveys among a representative sample of adults ≥ 18 years old in the US. We administered Rome IV gastroduodenal and bowel DGBI questionnaires (e.g., chronic idiopathic constipation [CIC], functional bloating, functional dyspepsia, irritable bowel syndrome [IBS]) along with sociodemographic and comorbidity questions. Multivariable logistic regression was used to adjust for time and potential confounders. Results: Overall, 160,154 people completed the surveys. During the COVID‐19 pandemic, the prevalence of IBS (6.1% [May 2020] to 11.0% [May 2022]; +0.188%/month; adjusted p < 0.001) and CIC (6.0% [May 2020] to 6.4% [May 2022]; +0.056%/month; adjusted p < 0.001) increased over time. Among those with IBS, the largest prevalence increase was seen in mixed IBS (+0.085%/month), followed by IBS with constipation (+0.041%/month) and IBS with diarrhea (+0.037%/month). No changes in prevalence were seen for the other examined gastroduodenal and bowel DGBI. Conclusions: During the COVID‐19 pandemic, we observed significant increases over time in the prevalence of IBS and CIC. Further research exploring pathophysiologic mechanisms underlying these findings and whether these trends persist beyond the pandemic is warranted.
- 10 March 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (4) , e70020
Trends in Prevalence of Rome IV Disorders of Gut‐Brain Interaction During the COVID‐19 Pandemic: Results From a Nationally Representative Sample of Over 160,000 People in the US
Background: We hypothesized that disorders of gut‐brain interaction (DGBI) increased during the pandemic due to the enteropathic nature of SARS‐CoV‐2, together with the potential for COVID‐19 pandemic‐related stress to negatively impact the gut‐brain axis. To test our hypothesis, we conducted a series of pre‐specified cross‐sectional surveys initiated at the beginning of the pandemic to trend the prevalence of Rome IV DGBI over time among a nationally representative sample of more than 160,000 people in the US. Methods: From May 2020 to May 2022, we performed a series of cross‐sectional online surveys among a representative sample of adults ≥ 18 years old in the US. We administered Rome IV gastroduodenal and bowel DGBI questionnaires (e.g., chronic idiopathic constipation [CIC], functional bloating, functional dyspepsia, irritable bowel syndrome [IBS]) along with sociodemographic and comorbidity questions. Multivariable logistic regression was used to adjust for time and potential confounders. Results: Overall, 160,154 people completed the surveys. During the COVID‐19 pandemic, the prevalence of IBS (6.1% [May 2020] to 11.0% [May 2022]; +0.188%/month; adjusted p < 0.001) and CIC (6.0% [May 2020] to 6.4% [May 2022]; +0.056%/month; adjusted p < 0.001) increased over time. Among those with IBS, the largest prevalence increase was seen in mixed IBS (+0.085%/month), followed by IBS with constipation (+0.041%/month) and IBS with diarrhea (+0.037%/month). No changes in prevalence were seen for the other examined gastroduodenal and bowel DGBI. Conclusions: During the COVID‐19 pandemic, we observed significant increases over time in the prevalence of IBS and CIC. Further research exploring pathophysiologic mechanisms underlying these findings and whether these trends persist beyond the pandemic is warranted.
- 6 February 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (4) , 341-348
Assessing the Impact of Media Coverage of the NordICC Trial on Public Perspectives on Colonoscopy for Colorectal Cancer Screening
Introduction: Screening tests like colonoscopy can prevent colorectal cancer (CRC), yet their effectiveness is often questioned. The Nordic-European Initiative on Colorectal Cancer (NordICC) trial demonstrated that colonoscopy significantly reduces CRC incidence and mortality in per-protocol analysis. However, media coverage of the trial often focused on intention-to-screen findings that showed no change in mortality, possibly contributing to public confusion about colonoscopy benefits. This study aimed to assess whether such media articles undermined public perception and intent to undergo colonoscopic screening. Methods: We recruited a US nationally representative sample of unscreened adults aged 45 to 75 years at average CRC risk. Respondents were randomized 1:1 to read either a low-quality or high-quality article on NordICC, as rated by a panel of gastroenterologists. Before and after reading their article, participants reported whether they plan to be screened for CRC with a colonoscopy. Our primary outcome was a negative change in intent to undergo colonoscopic screening. Results: Among the 2013 participants who completed the survey, 1531 (76.1%) stated they planned to undergo colonoscopy or were undecided before reading the article. After reading the media report, 90 (12.0%) people in the low-quality article arm no longer planned to undergo colonoscopy versus 73 (9.3%) in the high-quality article arm; the difference was not statistically significant ( P =0.08). Discussion: A widely promulgated article about NordICC rated as low-quality did not differentially impact attitudes towards colonoscopic CRC screening compared with another mainstream article rated as high-quality. Our study provides reassurance that most people will not summarily change health behaviors after reading a single article, regardless of perceived accuracy.
- 6 February 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (4) , 341-348
Assessing the Impact of Media Coverage of the NordICC Trial on Public Perspectives on Colonoscopy for Colorectal Cancer Screening
Introduction: Screening tests like colonoscopy can prevent colorectal cancer (CRC), yet their effectiveness is often questioned. The Nordic-European Initiative on Colorectal Cancer (NordICC) trial demonstrated that colonoscopy significantly reduces CRC incidence and mortality in per-protocol analysis. However, media coverage of the trial often focused on intention-to-screen findings that showed no change in mortality, possibly contributing to public confusion about colonoscopy benefits. This study aimed to assess whether such media articles undermined public perception and intent to undergo colonoscopic screening. Methods: We recruited a US nationally representative sample of unscreened adults aged 45 to 75 years at average CRC risk. Respondents were randomized 1:1 to read either a low-quality or high-quality article on NordICC, as rated by a panel of gastroenterologists. Before and after reading their article, participants reported whether they plan to be screened for CRC with a colonoscopy. Our primary outcome was a negative change in intent to undergo colonoscopic screening. Results: Among the 2013 participants who completed the survey, 1531 (76.1%) stated they planned to undergo colonoscopy or were undecided before reading the article. After reading the media report, 90 (12.0%) people in the low-quality article arm no longer planned to undergo colonoscopy versus 73 (9.3%) in the high-quality article arm; the difference was not statistically significant ( P =0.08). Discussion: A widely promulgated article about NordICC rated as low-quality did not differentially impact attitudes towards colonoscopic CRC screening compared with another mainstream article rated as high-quality. Our study provides reassurance that most people will not summarily change health behaviors after reading a single article, regardless of perceived accuracy.
- 1 December 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (1)
Comparing the efficacy of different proton pump inhibitor dosing regimens for the treatment of gastroesophageal reflux disease: a systematic review and meta-analysis
Summary: Several proton pump inhibitor (PPI) dosing regimens that vary by strength and frequency (once [Qday] or twice [BID] daily) are available to treat gastroesophageal reflux disease (GERD). We performed an updated systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the impact of various PPI regimens on esophageal healing and GERD and heartburn symptoms. To identify relevant studies, we searched EMBASE and PubMed in January 2023, which yielded 1381 records. Eligible RCTs included those that enrolled adults diagnosed with GERD and compared different dosing regimens within the same PPI. The outcomes were esophageal healing and resolution of GERD and heartburn symptoms within 12 weeks (i.e. short-term) and > 12 weeks (i.e. long-term). Meta-analysis pooling of the odds ratios with 95% confidence intervals were estimated using the random-effects inverse-variance model. Overall, a total of 38 RCTs across 20 countries (N = 15,540 patients, mean age 50 years, 55% male) were included. Most PPI trials compared half standard dose Qday versus standard dose Qday or standard dose Qday versus double standard dose Qday. In general, when considering daily dosing, higher PPI strength significantly improved esophageal healing and relief of GERD symptoms both in the short- and long-term. Fewer trials compared Qday versus BID dosing; the impact of BID dosing on outcomes was inconsistent across the different PPI strength comparisons. In conclusion, this meta-analysis revealed that increasing PPI Qday dosages led to improved GERD outcomes. However, few studies compared Qday to BID dosing; as twice daily PPI usage is common in clinical practice, further studies are warranted to determine whether such dosing improves clinical outcomes.
- 1 December 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (1)
Comparing the efficacy of different proton pump inhibitor dosing regimens for the treatment of gastroesophageal reflux disease: a systematic review and meta-analysis
Summary: Several proton pump inhibitor (PPI) dosing regimens that vary by strength and frequency (once [Qday] or twice [BID] daily) are available to treat gastroesophageal reflux disease (GERD). We performed an updated systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the impact of various PPI regimens on esophageal healing and GERD and heartburn symptoms. To identify relevant studies, we searched EMBASE and PubMed in January 2023, which yielded 1381 records. Eligible RCTs included those that enrolled adults diagnosed with GERD and compared different dosing regimens within the same PPI. The outcomes were esophageal healing and resolution of GERD and heartburn symptoms within 12 weeks (i.e. short-term) and > 12 weeks (i.e. long-term). Meta-analysis pooling of the odds ratios with 95% confidence intervals were estimated using the random-effects inverse-variance model. Overall, a total of 38 RCTs across 20 countries (N = 15,540 patients, mean age 50 years, 55% male) were included. Most PPI trials compared half standard dose Qday versus standard dose Qday or standard dose Qday versus double standard dose Qday. In general, when considering daily dosing, higher PPI strength significantly improved esophageal healing and relief of GERD symptoms both in the short- and long-term. Fewer trials compared Qday versus BID dosing; the impact of BID dosing on outcomes was inconsistent across the different PPI strength comparisons. In conclusion, this meta-analysis revealed that increasing PPI Qday dosages led to improved GERD outcomes. However, few studies compared Qday to BID dosing; as twice daily PPI usage is common in clinical practice, further studies are warranted to determine whether such dosing improves clinical outcomes.